RxDoctor Payments Data

Mutiat Popoola

Psychiatric/Mental Health · Brandywine, MDNPI 1477169936

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 34 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$269
  • Neurocrine Biosciences, Inc.$214
  • Teva Pharmaceuticals USA, Inc.$147
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
  • Alkermes, Inc.$107
  • Corium, LLC$90
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$1,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,102 in reported general payments places this provider in the 75th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$11,294
Medicare patients
33
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate52$155,647
Risperdal ConstaRisperidone Microspheres35$82,097
Abilify MaintenaAripiprazole31$78,171
Perphenazine75$9,478
Haloperidol Decanoate118$4,557
VyvanseLisdexamfetamine Dimesylate11$4,551
Quetiapine Fumarate133$4,429
Olanzapine124$3,756
Clozapine73$3,660
Divalproex Sodium83$3,532
Benztropine Mesylate245$3,351
Risperidone98$3,301
Fluphenazine Decanoate16$3,035
Lurasidone Hcl16$2,989
Fluvoxamine Maleate39$2,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$269$237,74487 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$37$78,17131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Brandywine

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →